Corporate Overview

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company developing products using its proprietary technology and innovative efforts to develop products to address unmet medical needs. The Company's Biochronomer® polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action of known active ingredients. The Company's lead product, SUSTOL® (granisetron injection, extended release), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting.

More>>

Stock Quote
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$9.27
Change (%) Stock is Down 0.03 (0.32%)
Volume157,800
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Calendar of Events
December 2014?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-1123456
78910111213
1415
12/15/14
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
16
12/16/14
4
Formats:  HTML Adobe PDF Word
17181920
21222324252627
28293031515253
Recent NewsMore >>
DateTitle 
12/02/14Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 2, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City. A live webcast of this presentation will be available on the Company’s website at www.herontx.com ... 
Printer Friendly Version
11/06/14Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 6, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeu... 
Printer Friendly Version
11/06/14Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nov. 6, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress. Third Quarter Highlights and Progress: Due to a slower rate of enrollment than projected over the last quarter for Heron’s ongoing Phase 3 study of SUSTOL® (granisetron injection, ext... 
Printer Friendly Version
08/25/14Heron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and Secretary
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 25, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esmé C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron’s Chief Executive Officer. “Esme brings to her role at Heron over fifteen years of relevant legal and industry experience that will... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.